+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

O2-8-1Ramucirumab (Ram) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (Hcc): Japanese subgroup analysis of the phase Iii Reach trial



O2-8-1Ramucirumab (Ram) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (Hcc): Japanese subgroup analysis of the phase Iii Reach trial



Annals of Oncology 26(Suppl 7): vii94.3-vii94




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067408216

Download citation: RISBibTeXText

DOI: 10.1093/annonc/mdv471.63


Related references

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. Journal of Gastroenterology 52(4): 494-503, 2017

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet. Oncology 16(7): 859-870, 2015

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncology 3(2): 235-243, 2017

L03Ramucirumab (Ram) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase Iii Reach Study. Annals of Oncology 26(Suppl 6): vi.80-vi, 2015

O-005 * Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study. Annals of Oncology 26(Suppl 4): Iv109-Iv109, 2015

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European Journal of Cancer 81: 17-25, 2017

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade. Journal of Hepatology 64(2): S693-S694, 2016

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. International Journal of Clinical Oncology 20(5): 905-912, 2015

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget 7(46): 75482-75491, 2016

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Targeted Oncology 12(2): 201-209, 2017

Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. Cancer 116(21): 5022-5029, 2010

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Oncology 20(2): 282-296, 2019

Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Japanese Journal of Clinical Oncology 41(1): 17-24, 2011

Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. Journal of Thoracic Oncology 5(5): 688-695, 2010

Data from a phase Ib/Ii trial of the oral c-Met inhibitor tepotinib (Msc2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma. European Journal of Cancer 51: S452-S453, 2015